In 2021, Delica was awarded as a national-level "Giant in Niche" enterprise by the Ministry of Industry and Information Technology for its innovative R&D capabilities, advanced technical level, and high market share.

Delica owns over 20 patents until the year of 2020. The company`s quality system passed the German TUV, ISO13485: 2012 certification and the main products also got the EU CE certification and the US FDA certification.

The National professional standard which is called "Transcranial Doppler Flow Analyzer YY / T0593-2015" was jointly revised by Wuhan National Ultrasonic Testing Center and Delica, and it began to implement in 2016.

The company`s Transcranial Doppler ultrasound systems reach the international leading level with CE and FDA certification; a large number of products were sold to the tertiary A hospitals and were exported to Europe and the United States. Over 10,000 domestic users in China and the international market share are in the top two. The market share was among the best in 2021 which included China, the United States, South Korea, the Netherlands, Hong Kong, and some other countries and regions.

Delica products are becoming more and more extensive in the application of academic research, and the number of published academic articles which had used Delica equipment from domestic and abroad are also increasing.

Delica has established a long-term cooperative research relationship with the Chinese Academy of Sciences, Aerospace Center Hospital, The Hong Kong Polytechnic University, The Chinese University of Hong Kong, Jilin University, Capital Medical University, Peking University, University of Cambridge, University of California, University of Southern Queensland, National Central University, South China University of Technology, etc.

The company`s product strategy is keeping server for global users and will strive to create an innovative diagnosis and treatment system that integrates neurological care and digital technology.

Delica Medica Corporation - Video